Cargando…
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
A recent study have reported that pre-use of azelastine is associated with a decrease in COVID-19 positive test results among susceptible elderly people. Besides, it has been reported that antihistamine drugs could prevent viruses from entering cells. The purpose of this study is to investigate whet...
Autores principales: | Ge, Shuai, Lu, Jiayu, Hou, Yajing, Lv, Yuexin, Wang, Cheng, He, Huaizhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144927/ https://www.ncbi.nlm.nih.gov/pubmed/34052578 http://dx.doi.org/10.1016/j.virol.2021.05.009 |
Ejemplares similares
-
Repositioning of histamine H(1) receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2
por: Ge, Shuai, et al.
Publicado: (2021) -
Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis
por: Hou, Yajing, et al.
Publicado: (2021) -
Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2
por: Zhang, Yongjing, et al.
Publicado: (2021) -
Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro
por: Lu, Jiayu, et al.
Publicado: (2021) -
Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus
por: Wang, Nan, et al.
Publicado: (2020)